New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
17:18 EDTIDXXIDEXX announces FTC preliminary approval of consent agreement
IDEXX Laboratories announced that the commissioners of the U.S. FTC have preliminarily approved the consent agreement previously reached between the company and the staff of the FTC Bureau of Competition. Pursuant to FTC protocol, a proposed draft complaint and the proposed consent agreement, which includes a draft consent order, will be placed on public record for a 30-day comment period, after which the FTC will evaluate any public comment before finalizing the agreement and order. "While we admit no wrongdoing and continue to believe that our distribution practices do not violate the antitrust laws as these same practices have been upheld in previous litigation victories, this is another important step toward final resolution of the multi-year FTC investigation, which we now expect to occur early in 2013," the company said.
News For IDXX From The Last 14 Days
Check below for free stories on IDXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
07:08 EDTIDXXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use